| Bid | 22.5 |
| Market Cap | 3.36B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.21 |
| PE Ratio (ttm) | -10.37 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 25 |
| Volume | 1,143,091 |
| Avg. Volume (20D) | 870,359 |
| Open | 23.00 |
| Previous Close | 22.75 |
| Day's Range | 22.82 - 24.99 |
| 52-Week Range | 22.41 - 42.44 |
| Beta | undefined |
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for...
Analyst Forecast
According to 10 analyst ratings, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 105.15% from the latest price.
2 weeks ago · seekingalpha.com
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal StudyImmunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402...
